Single shot antibiotic approved for skin infections


Intravenous antibiotic Orbactiv (oritavancin), from US firm The Medicines Company, has been approved by the US Food and Drug Administration (FDA). The drug can be used to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Orbactiv is the third drug to be approved (all for ABSSSIs) under the FDA’s incentive programme for encouraging companies to develop new antibiotics. It joins Durata Therapeutics' Dalvance (dalbavancin), which was approved in May, and Cubist’s Sivextro (tedizolid), approved in June. All three were designated as Qualified Infectious Disease Products, since they combat pathogens on the FDA’s list of serious or life-threatening infections. That designation entitles the companies to speedier reviews of their regulatory applications, as well as an extra five years’ market exclusivity to take into account the restricted use of new antibiotics limiting sales.

Orbactiv and Dalvance are intravenous drugs with structures related to the current drug of last resort, vancomycin. Both are administered intravenously – Orbactiv in a single dose, compared to three infusions of Dalvance or 7–10 days of twice-daily vancomycin infusions. Sivextro is approved for both oral and intravenous use.


Related Content

Re-arming the antibiotic arsenal

26 September 2013 Feature

news image

How can we make new antibiotics? Phillip Broadwith takes a look

Making light work

1 April 2012 Feature

news image

Could light prove to be the ultimate weapon in the battle against deadly superbugs?

Most Read

Quintuple bond activates small stable molecules

19 September 2014 Research

news image

Exotic complexes suggest route to synthetic feedstock

Computer simulations point to formamide as prebiotic intermediate in ‘Miller’ mixtures

16 September 2014 News and Analysis

news image

Electric field may have provided more than just energy for primordial chemistry

Most Commented

US genomics lead being lost to China

17 September 2014 News and Analysis

news image

NIH senior leaders are sounding the alarm bells, saying the US's pre-eminence in genomics research is under threat

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow